ArticleJAMA psychiatry2023
Timing of Antidepressant Discontinuation During Pregnancy and Postpartum Psychiatric Outcomes in Denmark and Norway.
Article in JAMA psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study.European heart journal · 2026Pooled it
- Descriptive Characteristics of Psychiatric Medication Discontinuation Among Perinatal Women With Depressive Symptoms.Early intervention in psychiatry · 2025Trial
- Neonatal Outcomes Following Selective Serotonin Reuptake Inhibitor Use During Pregnancy.JAMA network open · 2026Article
- Continuation and discontinuation of antidepressant treatment before, during and after pregnancy: a cohort study.Archives of women's mental health · 2026Article
- Development of a novel adherence scale for antidepressants in pregnancy: Results from a cross-sectional study.Exploratory research in clinical and social pharmacy · 2026Article
- Real-World Data Insights into Antidepressant Prescription and Adherence During Pregnancy in Catalonia (Spain).Drug safety · 2025Observational
- Gender-specific addiction research needed now more than ever: Reflections from 25 years of the NIDA Clinical Trials Network Gender Special Interest Group.Journal of substance use and addiction treatment · 2025Article
- Identifying medication use clusters with the R package tame based on dose, timing and ATC codes.Scientific reports · 2025Article
- Antidepressants Use Among Pregnant Women in Denmark From 2001 to 2023: A Population-Level Drug Utilization Study.Basic & clinical pharmacology & toxicology · 2025Article
- Psychotropic Medication Exposure via Breast Milk: A Population-Based Descriptive Study in Denmark.Paediatric and perinatal epidemiology · 2025Article
- Review
- Changes in S-Citalopram Plasma Concentrations Across Pregnancy and Postpartum.Clinical pharmacology and therapeutics · 2025Observational
- Safety in treatment: Classical pharmacotherapeutics and new avenues for addressing maternal depression and anxiety during pregnancy.Pharmacological reviews · 2025Review
- Antidepressant Use Before, During, and After Pregnancy.JAMA network open · 2025Article
- Measuring the continuation of antidepressant exposure prior to, during, and after pregnancy: A scoping review protocol.PloS one · 2025Article
- Social determinants of antidepressant continuation during pregnancy in the USA: findings from the ABCD cohort study.Archives of women's mental health · 2024Article
- Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross national cohort study.BMJ (Clinical research ed.) · 2024Article
- Postpartum Psychiatric Outcomes and Sick Leave After Discontinuing SSRI or SNRI in Pregnancy.JAMA network open · 2024Article
- Partner support for women's antidepressant treatment and its association with depressive symptoms in pregnant women, mothers, and women planning pregnancy.Archives of women's mental health · 2024Article
- Impact of genetic, sociodemographic, and clinical features on antidepressant treatment trajectories in the perinatal period.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
Abstract
Importance: Approximately one-half of women treated for affective disorders discontinue antidepressant use during pregnancy, yet this discontinuation could lead to relapse post partum. Objective: To investigate the associations between longitudinal antidepressant fill trajectories during pregnancy and postpartum psychiatric outcomes. Design, Setting, and Participants: This cohort study used nationwide registers in Denmark and Norway. The sample included 41 475 live-born singleton pregnancies in Denmark (1997-2016) and 16 459 in Norway (2009-2018) for women who filled at least 1 antidepressant prescription within 6 months before pregnancy. Exposures: Antidepressant prescription fills were obtained from the prescription registers. Antidepressant treatment during pregnancy was modeled using the k-means longitudinal method. Main Outcomes and Measures: Initiation of psycholeptics, psychiatric emergencies, or records of self-harm within 1 year post partum. Between April 1 and October 30, 2022, hazard ratios (HRs) for each psychiatric outcome were estimated using Cox proportional hazards regression models. Inverse probability of treatment weighting was used to control for confounding. Country-specific HRs were pooled using random-effects meta-analytic models. Results: Among 57 934 pregnancies (mean [SD] maternal age, 30.7 [5.3] years in Denmark and 29.9 [5.5] years in Norway), 4 antidepressant fill trajectories were identified: early discontinuers (31.3% and 30.4% of the included pregnancies in Denmark and Norway, respectively), late discontinuers (previously stable users) (21.5% and 27.8%), late discontinuers (short-term users) (15.9% and 18.4%), and continuers (31.3% and 23.4%). Early discontinuers and late discontinuers (short-term users) had a lower probability of initiating psycholeptics and having postpartum psychiatric emergencies vs continuers. A moderately increased probability of initiation of psycholeptics was found among late discontinuers (previously stable users) vs continuers (HR, 1.13; 95% CI, 1.03-1.24). This increase in late discontinuers (previously stable users) was more pronounced among women with previous affective disorders (HR, 1.28; 95% CI, 1.12-1.46). No association between antidepressant fill trajectories and postpartum self-harm risk was found. Conclusions and Relevance: Based on pooled data from Denmark and Norway, a moderately elevated probability of initiation of psycholeptics in late discontinuers (previously stable users) vs continuers was found. These findings suggest that women with severe mental illness who are currently on stable treatment may benefit from continuing antidepressant treatment and personalized treatment counseling during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.